SPPI
Price:
$1.025
Market Cap:
$210.38M
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license...[Read more]
Industry
Biotechnology
IPO Date
1996-09-26
Stock Exchange
NASDAQ
Ticker
SPPI
According to Spectrum Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 186.84M. This represents a change of 113.16% compared to the average of 87.65M of the last 4 quarters.
The mean historical Enterprise Value of Spectrum Pharmaceuticals, Inc. over the last ten years is 456.00M. The current 186.84M Enterprise Value has changed 4.00% with respect to the historical average. Over the past ten years (40 quarters), SPPI's Enterprise Value was at its highest in in the June 2018 quarter at 2.02B. The Enterprise Value was at its lowest in in the September 2022 quarter at 53.98M.
Average
456.00M
Median
366.37M
Minimum
56.58M
Maximum
1.42B
Discovering the peaks and valleys of Spectrum Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 444.63%
Maximum Annual Enterprise Value = 1.42B
Minimum Annual Increase = -71.18%
Minimum Annual Enterprise Value = 56.58M
Year | Enterprise Value | Change |
---|---|---|
2022 | 56.58M | -48.29% |
2021 | 109.42M | -71.18% |
2020 | 379.69M | 10.97% |
2019 | 342.17M | -54.16% |
2018 | 746.45M | -47.58% |
2017 | 1.42B | 444.63% |
2016 | 261.43M | -25.95% |
2015 | 353.05M | -14.88% |
2014 | 414.78M | -12.24% |
2013 | 472.63M | -19.99% |
The current Enterprise Value of Spectrum Pharmaceuticals, Inc. (SPPI) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
181.90M
5-year avg
326.86M
10-year avg
456.00M
Spectrum Pharmaceuticals, Inc.’s Enterprise Value is greater than Selecta Biosciences, Inc. (69.24M), less than Paratek Pharmaceuticals, Inc. (344.90M), less than Corvus Pharmaceuticals, Inc. (237.94M), less than Immutep Limited (412.67M), less than Icosavax, Inc. (713.87M), less than Ardelyx, Inc. (1.38B), greater than Zura Bio Limited (42.42M), greater than Hepion Pharmaceuticals, Inc. (2.24M), greater than AVROBIO, Inc. (-85302404.00), greater than Verastem, Inc. (55.08M), less than Agios Pharmaceuticals, Inc. (2.44B), less than bluebird bio, Inc. (240.30M), less than Intercept Pharmaceuticals, Inc. (915.81M), less than Karyopharm Therapeutics Inc. (201.87M), less than BioLineRx Ltd. (0), greater than Lexicon Pharmaceuticals, Inc. (77.24M), less than Seres Therapeutics, Inc. (652.06M), less than ImmunityBio, Inc. (286.75M), less than Gamida Cell Ltd. (3.22B), greater than Rigel Pharmaceuticals, Inc. (57.65M), less than Geron Corporation (258.64M), less than ImmunoGen, Inc. (2.53B), less than null (8.19B),
Company | Enterprise Value | Market cap |
---|---|---|
69.24M | $135.20M | |
344.90M | $127.83M | |
237.94M | $252.08M | |
412.67M | $382.21M | |
713.87M | $769.04M | |
1.38B | $1.32B | |
42.42M | $230.86M | |
2.24M | $4.20M | |
-85302404.00 | $5.24M | |
55.08M | $96.58M | |
2.44B | $2.46B | |
240.30M | $101.94M | |
915.81M | $794.69M | |
201.87M | $91.04M | |
0 | $55.61M | |
77.24M | $582.00M | |
652.06M | $145.36M | |
286.75M | $2.35B | |
3.22B | $4.34M | |
57.65M | $234.37M | |
258.64M | $2.56B | |
2.53B | $8.73B | |
8.19B | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spectrum Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Spectrum Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Spectrum Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Spectrum Pharmaceuticals, Inc. (SPPI)?
What is the 3-year average Enterprise Value for Spectrum Pharmaceuticals, Inc. (SPPI)?
What is the 5-year average Enterprise Value for Spectrum Pharmaceuticals, Inc. (SPPI)?
How does the current Enterprise Value for Spectrum Pharmaceuticals, Inc. (SPPI) compare to its historical average?